Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-κB pathway modulation

International Journal of Oncology

Volumn 48, Issue 2, 2016, Pages 756-764

  Zhao, Ming ^a   Fan, Juan ^a   Liu, Yong ^a   Yu, Yanxin ^a   Xu, Jinhui ^a   Wen, Qinglian ^a   Zhang, Jianwen ^a   Fu, Shaozhi ^a   Wang, Biqiong ^a   Xiang, Li ^a   Feng, Jing ^a   Wu, Jingbo ^a   Yang, Linglin ^a  

^a First Affiliated Hospital of Luzhou Medical College   (China)

Author keywords

Nasopharyngeal carcinoma; NF B pathway; TP53 induced glycolysis and apoptosis regulator; Xenograft model

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SHORT HAIRPIN RNA; APOPTOSIS REGULATORY PROTEIN; C12ORF5 PROTEIN, HUMAN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TP53 INDUCED GLYCOLYSIS AND APOPTOSIS REGULATOR; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; GLYCOLYSIS; METABOLISM; NASOPHARYNX TUMOR; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GLYCOLYSIS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NF-KAPPA B; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84956924727     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3297     Document Type: Article

References (29)

1. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D, et al: Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71: 3162-3172, 2011.
2. X iao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C: Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: Long-term results of a phase 2 study. Cancer 117: 1874-1883, 2011.
3. Lee AW, Lin JC and Ng WT: Current management of nasopharyngeal cancer. Semin Radiat Oncol 22: 233-244, 2012.
4. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E and Vousden KH: TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120, 2006.
5. Vousden KH and Ryan KM: p53 and metabolism. Nat Rev Cancer 9: 691-700, 2009.
6. Won KY, Lim SJ, Kim GY, Kim YW, Han SA, Song JY and Lee DK: Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer. Hum Pathol 43: 221-228, 2012.
7. Ye L, Zhao X, Lu J, Qian G, Zheng JC and Ge S: Knockdown of TIGAR by RNA interference induces apoptosis and autophagy in HepG2 hepatocellular carcinoma cells. Biochem Biophys Res Commun 437: 300-306, 2013.
8. Cheung EC, Athineos D, Lee P, Ridgway RA, Lambie W, Nixon C, Strathdee D, Blyth K, Sansom OJ and Vousden KH: TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell 25: 463-477, 2013.
9. Wanka C, Steinbach JP and Rieger J: Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem 287: 33436-33446, 2012.
10. Sinha S, Ghildiyal R, Mehta VS and Sen E: ATM-NFκB axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNFα. Cell Death Dis 4: e615, 2013.
11. Pena-Rico MA, Calvo-Vidal MN, Villalonga-Planells R, Martinez-Soler F, Gimenez-Bonafe P, Navarro-Sabate A, Tortosa A, Bartrons R and Manzano A.. TP53 induced glycolysis and apoptosis regulator (TIGAR) knockdown results in radiosensitization of glioma cells. Radiother Oncol 101: 132-139, 2011.
12. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9: 6371-6380, 2003.
13. Somasundaram K and El-Deiry WS: Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/ CBP-interacting region. Oncogene 14: 1047-1057, 1997.
14. Kimata M, Matoba S, Iwai-Kanai E, Nakamura H, Hoshino A, Nakaoka M, Katamura M, Okawa Y, Mita Y, Okigaki M, et al: p53 and TIGAR regulate cardiac myocyte energy homeostasis under hypoxic stress. Am J Physiol Heart Circ Physiol 299: H1908-H1916, 2010.
15. Lui VW, Lau CP, Cheung CS, Ho K, Ng MH, Cheng SH, Hong B, Tsao SW, Tsang CM, Lei KI, et al: An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl) cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation. Biochem Pharmacol 79: 1772-1780, 2010.
16. Lui VW, Wong EY, Ho K, Ng PK, Lau CP, Tsui SK, Tsang CM, Tsao SW, Cheng SH, Ng MH, et al: Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene 30: 1127-1134, 2011.
17. Yin L, Kosugi M and Kufe D: Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood 119: 810-816, 2012.
18. Bensaad K, Cheung EC and Vousden KH: Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J 28: 3015-3026, 2009.
19. Napetschnig J and Wu H: Molecular basis of NF-κB signaling. Annu Rev Biophys 42: 443-468, 2013.
20. Jacobs MD and Harrison SC: Structure of an IkappaBalpha/ NF-kappaB complex. Cell 95: 749-758, 1998.
21. Perkins ND and Gilmore TD: Good cop, bad cop: The different faces of NF-kappaB. Cell Death Differ 13: 759-772, 2006.
22. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
23. Li F, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS and Sethi G: NF-κB in cancer therapy. Arch Toxicol 89: 711-731, 2015.
24. Ren Q, Sato H, Murono S, Furukawa M and Yoshizaki T: Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. Laryngoscope 114: 855-859, 2004.
25. Lo AK, Lo KW, Tsao SW, Wong HL, Hui JW, To KF, Hayward DS, Chui YL, Lau YL, Takada K, et al: Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8: 173-180, 2006.
26. Cheung AK, Ko JM, Lung HL, Chan KW, Stanbridge EJ, Zabarovsky E, Tokino T, Kashima L, Suzuki T, Kwong DL, et al: Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-kappaB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis. Proc Natl Acad Sci USA 108: 8390-8395, 2011.
27. Sun W, Guo MM, Han P, Lin JZ, Liang FY, Tan GM, Li HB, Zeng M and Huang XM: Id-1 and the p65 subunit of NF-κB promote migration of nasopharyngeal carcinoma cells and are correlated with poor prognosis. Carcinogenesis 33: 810-817, 2012.
28. Kan R, Shuen WH, Lung HL, Cheung AK, Dai W, Kwong DL, Ng WT, Lee AW, Yau CC, Ngan RK, et al: NF-κB p65 subunit is modulated by latent transforming growth factor-β binding protein 2 (LTBP2) in nasopharyngeal carcinoma HONE1 and HK1 cells. PLoS One 10: e0127239, 2015.
29. Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942, 2004.